ODTX (Odyssey Therapeutics) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)


ODTX Odyssey Therapeutics Inc ODTX
9 GF Score
Price $19.23
! 2 Warning Signs
View Full Analysis

What is Odyssey Therapeutics ROE % Adjusted to Book Value?

Odyssey Therapeutics ODTX +1.91% 9 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates ODTX with a GF Score™ of 9/100. The stock has 2 warning signs investors should review.

Odyssey Therapeutics's ROE % for the quarter that ended in Mar. 2026 was 0.00%. Odyssey Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was N/A. Odyssey Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

Odyssey Therapeutics ROE % Adjusted to Book Value Related Terms

Odyssey Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Odyssey Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Odyssey Therapeutics ROE % Adjusted to Book Value Chart

Odyssey Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00 0.00

Odyssey Therapeutics Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

ODTX vs VOR, PHAT, GERN: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Odyssey Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Odyssey Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Odyssey Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Odyssey Therapeutics's ROE % Adjusted to Book Value falls into.


ODTX
9GF Score
Odyssey Therapeutics Inc ODTX
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Odyssey Therapeutics ROE % Adjusted to Book Value Calculation

Odyssey Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Odyssey Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Odyssey Therapeutics (ODTX) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Odyssey Therapeutics and its competitors.
Is Odyssey Therapeutics' ROE % Adjusted to Book Value too high?
Odyssey Therapeutics' current ROE % Adjusted to Book Value is 0.00%. Overall, Odyssey Therapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Odyssey Therapeutics' ROE % Adjusted to Book Value compare to VOR and PHAT?
Odyssey Therapeutics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Odyssey Therapeutics and its competitors. Odyssey Therapeutics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Odyssey Therapeutics stock overvalued right now?
Odyssey Therapeutics (ODTX) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Odyssey Therapeutics' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Odyssey Therapeutics (ODTX), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Odyssey Therapeutics Business Description

Address 51 Sleeper Street, Boston, MA, USA, 02210
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
9GF Score

Get the complete analysis for ODTX

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.23
Price